Matthias Emanuel Liechti (born 27 May 1970) is a Swiss scientist and physician who studies psychedelics, entactogens, and other psychoactive drugs.[1][2] He is the head of the Liechti Lab at the University of Basel in Switzerland.[1][3] The lab conducts in-vitro research, animal studies, and clinical studies of psychoactive drugs.[3] They have conducted clinical studies of drugs including LSD, psilocybin, mescaline, dimethyltryptamine (DMT), and MDMA.[2] The lab also characterizes novel psychoactive substances (designer drugs).[2]
Liechti is a professor of clinical pharmacology and internal medicine and an attending physician at the University of Basel.[1] He attended and underwent training at the University of California, San Diego and the University Hospital of Zurich, among other institutions.[1]
In April 2020, the Liechti Lab entered an agreement and long-term partnership with the psychedelic pharmaceutical company MindMed such that MindMed would have exclusive rights to the lab's data, compounds, and patent rights.[1][3] One such project is a psychedelic "neutralizer" technology that can abort or shorten a psychedelic experience.[1][3][4][5]